Tuesday, May 5, 2026

Trump’s 15% Profit Reclaim on AI Chip Exports to China Called Unconstitutional

Trump's plan to tax AI chip exports to China violates the Constitution, and legal experts predict lawsuits from shareholders.

How Huawei’s 5G Advanced Will Transform AI Connectivity Before 6G Arrives

Huawei urges early adoption of 5G Advanced to meet AI demands, predicting explosive growth in AI and emphasizing network upgrades.

Why Did North Korea Allow Russian Tourists to Run in Pyongyang Despite Marathon Cancellation?

North Korea canceled the Pyongyang Marathon but allowed 50 Russian tourists to participate in an alternative sports program in Pyongyang.

Tag: Nesuparib

North KoreaKoreaKimMilitarySouth KoreaAImarketrelationsInternational

Nesuparib: The Revolutionary Dual-Inhibitor for Pancreatic Cancer – Can It Outperform Existing Treatments?

Nesuparib shows promise in inhibiting pancreatic cancer metastasis, offering hope for patients regardless of BRCA mutation status.

Nesuparib: The Game-Changing Cancer Treatment for Small Cell Lung Cancer Revealed at AACR 2026

Onconic Therapeutics reveals Nesuparib's promising preclinical results for small cell lung cancer, outperforming existing treatments significantly.

Next-Gen Cancer Drug Nesuparib: How It Outperforms Olaparib in SCLC and Pancreatic Cancer

Onconic Therapeutics will present Nesuparib research at AACR 2026, showcasing its potential for various cancers and overcoming PARP inhibitor limitations.

Nesuparib: A Game-Changer in Cancer Treatment? Key Findings from AACR 2026

Onconic Therapeutics' Nesuparib shows promising results against small cell lung and pancreatic cancers, highlighting its competitive edge.

Nesuparib vs. Traditional Treatments: Will This New Dual-Target Cancer Drug Change the Game for Ovarian Cancer?

Onconic Therapeutics advances Nesuparib into Phase 2 trials for ovarian cancer, aiming to validate a novel re-maintenance therapy approach.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.